Related Experiment Video
Updated: Oct 13, 2025

Comparing Bibliometric Analysis Using PubMed, Scopus, and Web of Science Databases
Published on: October 24, 2019
Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan
Imad Treish1, Abeer Al Rabayah2, Saad Jaddoua1
1Department of Pharmacy, Center for Drug Policy and Technology Assessment (CDPTA), King Hussein Cancer Center, Amman, Jordan.
Abstract:
Rising prices of novel cancer medications are increasing the economic burden from cancer in Jordan, risking the ability of cancer patients to access lifesaving and life-extending treatments. Furthermore, in the absence of a national health technology assessment (HTA) framework, medication prices in Jordan are set based on manufacturers' pricing considerations and not a value proposition. In response to these challenges, King Hussein Cancer Center (KHCC), the de facto national cancer institute, developed a first-in-country, cancer-specific, cost-effectiveness threshold (CET) to aid institutional decision makers in approving only cost-effective medications. Over the past 10 years, cost-effectiveness analyses based on this CET have led to the introduction of > 70% of requested novel cancer medications after manufacturers agreed to lower prices, beyond registration prices, to meet the CET. Future work is warranted to empirically derive a CET for Jordan to better guide reimbursement decisions.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pharmaceutical Equivalents
Treatment Resistant Cancers
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

